203 results on '"Merkelbach-Bruse, Sabine"'
Search Results
2. TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases
3. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung
4. Reply to Fumihiko Urabe, Takashi Yoshioka, and Takahiro Kimura’s Letter to the Editor re: Felix Seelemeyer, David Pfister, Robert Pappesch, Sabine Merkelbach-Bruse, Pia Paffenholz and Axel Heidenreich. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021
5. TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading
6. 970 Multiplex-immunofluorescence-based spatial characterization of the tumor-microenvironment of a large bicentric clinical non-small cell lung cancer cohort
7. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer
8. Testing for deficient mismatch repair and microsatellite instability
9. Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
10. Erratum zu: Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität
11. Testing deficient mismatch repair and microsatellite instability
12. Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer
13. MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition
14. Overview of Molecular Detection Technologies for MET in Lung Cancer
15. MP33-14 EVALUATION OF miRNA-371a-3p (miR371a) ASSAY TO PREDICT FINAL PATHOHISTOLOGY IN PATIENTS UNDERGOING PRIMARY NERVE-SPARING RETROPERITONEAL LYMPHADENECTOMY (nsRPLND) FOR STAGE IIA/B SEMINOMAS AND NON-SEMINOMAS
16. Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report
17. Genomic Applications in Pulmonary Malignancies
18. Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
19. Supplemental Table 8 from Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
20. Supplementary Figure 2 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
21. Supplementary Data from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
22. Supplement from Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
23. Supplement from Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
24. Supplementary Data from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
25. Supplementary Figure 4 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
26. Evaluation of miRNA-371a-3p (miR371a) assay to predict final pathohistology in patients undergoing primary nerve-sparing retroperitoneal lymphadenectomy (nsRPLND) for stage IIA/B seminomas and non-seminomas.
27. Genomic ALK alterations in primary and relapsed neuroblastoma
28. Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors
29. ROS1: Rearrangements und Analytik
30. Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
31. Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
32. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial
33. Teenage-Onset Colorectal Cancers in a Digenic Cancer Predisposition Syndrome Provide Clues for the Interaction between Mismatch Repair and Polymerase δ Proofreading Deficiency in Tumorigenesis
34. Multicenter Evaluation of the Idylla GeneFusion in Non–Small-Cell Lung Cancer
35. Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data.
36. Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
37. Reply to: “Survival Analysis of TP53 Co-Mutations Should be Interpreted More Cautiously”
38. Metastatic patterns plus clinical and molecular characteristics of ROS1 aberrations in non-small cell lung cancer patients without rearrangements.
39. Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics
40. Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC
41. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
42. Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors
43. Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
44. Genomic Applications in Pulmonary Malignancies
45. MSI testing
46. Reference standards for gene fusion molecular assays on cytological samples: an international validation study
47. Biomarkers for Homologous Recombination Deficiency in Cancer
48. Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
49. Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
50. MSI-Testung
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.